Comparison of psychedelic and near-death or other non-ordinary experiences in changing attitudes about death and dying
In a large online survey of 3,192 people who had either psychedelic-occasioned or non-drug near-death/other non-ordinary experiences that changed their beliefs about death, both types produced comparable reductions in fear of death and high ratings of personal meaning and positive persisting effects, although psychedelic experiences elicited stronger mystical/near-death subjective features while non-drug events were more often rated the single most meaningful life event. Among psychedelics, ayahuasca and DMT tended to produce stronger and more positive enduring consequences than psilocybin and LSD; the authors suggest these characterisations support prospective psychedelic administration studies.
Authors
- Roland Griffiths
- Sandeep Nayak
- Thomas Swift
Published
Abstract
Both psychedelic drug experiences and near-death experiences can occasion changes in perspectives on death and dying, but there have been few direct comparisons of these phenomena. This study directly compared psychedelic occasioned and non-drug experiences which altered individuals’ beliefs about death. Individuals who reported an experience that altered their beliefs about death occasioned by either a psychedelic drug or a near-death or other non-ordinary experience completed an online survey. Circumstances of the experience, mystical and near-death subjective features, changes in attitudes about death, and other persisting effects were evaluated. The study sample (n = 3192) included five groups: non-drug near-death or other non-ordinary experiences (n = 933), and drug experiences occasioned by lysergic acid diethylamide (LSD) (n = 904), psilocybin (n = 766), ayahuasca (n = 282), or N,N-dimethyltryptamine (DMT) (n = 307). Analyses of differences in experiences were adjusted statistically for demographic differences between groups. Compared to the psychedelic groups, the non-drug group was more likely to report being unconscious, clinically dead, and that their life was in imminent danger. The groups were remarkably similar in the reported changes in death attitudes attributed to the experience, including a reduced fear of death and high ratings of positive persisting effects and personal meaning, spiritual significance, and psychological insight. Although both psychedelic and non-drug participants showed robust increases on standardized measures of mystical and near-death experiences, these measures were significantly greater in the psychedelic participants. Non-drug participants were more likely to rate their experiences as the single most meaningful of their lives. Comparing across psychedelic substances, ayahuasca and DMT groups tended report stronger and more positive enduring consequences of the experience than the psilocybin and LSD groups, which were largely indistinguishable. These data provide a detailed characterization and comparison of psychedelic occasioned and non-drug experiences that changed attitudes about death and suggest the importance of future prospective psychedelic administration studies.
Research Summary of 'Comparison of psychedelic and near-death or other non-ordinary experiences in changing attitudes about death and dying'
Introduction
Classic psychedelics such as psilocybin, lysergic acid diethylamide (LSD), and N,N-dimethyltryptamine (DMT) can occasion a wide range of acute subjective effects, including mystical-type experiences characterised by unity, sacredness, ineffability, and transcendence of time and space. Prior controlled research has linked drug‑occasioned mystical experiences to persistent positive changes in attitudes, mood and behaviour, and clinical trials with psilocybin have shown reductions in death anxiety among patients with life‑threatening illness. Separately, spontaneous non‑drug phenomena such as near‑death experiences (NDEs) and out‑of‑body experiences can produce similar enduring changes in attitudes about death; the Greyson Near‑Death Experience Scale was developed to quantify common phenomenological features of such events. Despite overlapping phenomenology and therapeutic interest, few studies have directly compared psychedelic‑occasioned experiences with non‑drug near‑death or other non‑ordinary experiences on common quantitative metrics. Sweeney and colleagues designed the present study to fill that gap by directly comparing people who reported a single experience that fundamentally changed their beliefs about death and dying, where the experience was either occasioned by a classic psychedelic (psilocybin, LSD, ayahuasca, or non‑ayahuasca DMT) or was a near‑death or other non‑ordinary experience occurring without psychedelic drugs. The investigation aimed to characterise contextual features of the experiences, acute phenomenology using standard instruments (for example the Mystical Experience Questionnaire and the Greyson NDE Scale), changes in death attitudes (using the Revised Death Attitude Profile, DAP‑R), and persisting personal and spiritual consequences attributed to the experience.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Compounds
- Topics
- Authors
- APA Citation
Sweeney, M. M., Nayak, S., Hurwitz, E. S., Mitchell, L. N., Swift, T. C., & Griffiths, R. R. (2022). Comparison of psychedelic and near-death or other non-ordinary experiences in changing attitudes about death and dying. PLOS ONE, 17(8), e0271926. https://doi.org/10.1371/journal.pone.0271926
References (27)
Papers cited by this study that are also in Blossom
Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2015)
Barrett, F. S., Griffiths, R. R. · Current Topics in Behavioral Neurosciences (2017)
Aday, J. S., Davis, A. K., Mitzkovitz, C. M. et al. · ACS Pharmacology and Translational Science (2021)
Carhart-Harris, R. L., Roseman, L., Haijen, E. C. H. M. et al. · Journal of Psychopharmacology (2018)
Haijen, E. C. H. M., Kaelen, M., Roseman, L. et al. · Frontiers in Pharmacology (2018)
Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K. et al. · Neuroscience and Biobehavioral Reviews (2020)
Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Psychopharmacology (2011)
Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Journal of Psychopharmacology (2017)
Yaden, D. B., Griffiths, R. R. · ACS Pharmacology and Translational Science (2020)
Carhart-Harris, R. L. · Current Opinion in Psychiatry (2019)
Show all 27 referencesShow fewer
Johnson, M. W., Hendricks, P. S., Barrett, F. S. et al. · Pharmacology and Therapeutics (2019)
Doss, M. K., Madden, M. B., Gaddis, A. et al. · Brain (2021)
Griffiths, R. R. · Journal of Psychopharmacology (2008)
Gasser, P., Holstein, D., Michel, Y. et al. · Journal of Nervous and Mental Disease (2014)
Griffiths, R. R., Johnson, M. W. · Journal of Psychopharmacology (2016)
Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)
Ross, S., Bossis, A. P., Guss, J. et al. · Journal of Psychopharmacology (2016)
Reiche, S., Hermle, L., Gutwinski, S. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2018)
Griffiths, R. R., Hurwitz, E. S., Davis, A. K. et al. · PLOS ONE (2019)
Davis, A. K., Clifton, J. M., Weaver, E. G. et al. · Journal of Psychopharmacology (2020)
Martial, C., Cassol, H., Charland-Verville, V, Erowid, E. et al. · Consciousness and Cognition (2019)
Timmermann, C., Roseman, L., Williams, L. et al. · Frontiers in Psychology (2018)
Zamberlan, F., Sanz, C., Pallavicini, C. et al. · Frontiers in Integrative Neuroscience (2018)
Strassman, R. J., Qualls, C. R., Uhlenhuth, E. H. et al. · JAMA Psychiatry (1994)
Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)
MacLean, K. A., Leoutsakos, J. S., Johnson, M. W. et al. · Journal for the Scientific Study of Religion (2012)
Moreton, S. G., Szalla, L., Menzies, R. E. et al. · Psychopharmacology (2019)
Cited By (8)
Papers in Blossom that reference this study
Griffiths, R. R., Jesse, R., Richards, W. A. et al. · Psychedelic Medicine (2026)
Dor-Ziderman, Y., David, J., Berkovich-Ohana, A. · Psychopharmacology (2025)
Neitzke-Spruill, L., Beit, C., Robinson, J. et al. · Neuroethics (2024)
Letheby, C. · Neuroethics (2024)
Moreton, S. G., Barr, N., Giese, K. J. · Death Studies (2024)
Nayak, S., Jackson, H., Griffiths, R. R. et al. · Journal of Psychoactive Drugs (2024)
David, J., Bouso, J. C., Kohek, M. et al. · Frontiers in Psychiatry (2023)
Moreton, S. G., Burden-Hill, A., Menzies, R. E. · Clinical Psychologist (2022)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.